Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity; D001221:Aspartate Carbamoyltransferase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005910:Glioma / Q000188:drug therapy* / Q000201:enzymology; D006084:Graft Rejection; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000201:enzymology; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use* / Q000633:toxicity
D000964:Antimetabolites, Antineoplastic; D009943:Organophosphorus Compounds; D001224:Aspartic Acid; C013195:sparfosic acid; D003520:Cyclophosphamide; D001221:Aspartate Carbamoyltransferase; D010746:Phosphonoacetic Acid